APA

Wang Y., Janku F., Piha-Paul S., Hess K., Broaddus R., Liu L., Shi N., Overman M., Kopetz S., Subbiah V., Naing A., Hong D., Tsimberidou A. M., Karp D., Yao J. & Fu S. (20201112). Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. : Scientific reports.

Chicago

Wang Yudong, Janku Filip, Piha-Paul Sarina, Hess Kenneth, Broaddus Russell, Liu Lidong, Shi Naiyi, Overman Michael, Kopetz Scott, Subbiah Vivek, Naing Aung, Hong David, Tsimberidou Apostolia M, Karp Daniel, Yao James and Fu Siqing. 20201112. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. : Scientific reports.

Harvard

Wang Y., Janku F., Piha-Paul S., Hess K., Broaddus R., Liu L., Shi N., Overman M., Kopetz S., Subbiah V., Naing A., Hong D., Tsimberidou A. M., Karp D., Yao J. and Fu S. (20201112). Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. : Scientific reports.

MLA

Wang Yudong, Janku Filip, Piha-Paul Sarina, Hess Kenneth, Broaddus Russell, Liu Lidong, Shi Naiyi, Overman Michael, Kopetz Scott, Subbiah Vivek, Naing Aung, Hong David, Tsimberidou Apostolia M, Karp Daniel, Yao James and Fu Siqing. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. : Scientific reports. 20201112.